Skip to main content
Premium Trial:

Request an Annual Quote

Genomica Posts Q2 Revenue Rise

NEW YORK, Aug. 7 – Genomica Corporation's revenue jumped 17 percent to $464,000 for the second quarter 2001, compared to $396,000 recorded in the year-ago period, the company said on Tuesday.

The Boulder, Colo.-based company attributed the revenue rise to licensing fees from its LinkMapper software and consulting fees from its alliance with Applied Biosystems.

Genomica registered second-quarter net losses of $5.8 million, or 26 cents per share, compared to $7.1 million, or $5.30 per share, year over year. This missed by 9 cents the net loss predicted by analysts polled by Thomson Financial/First Call.

Research and development increased slightly to $3.7 million from $3.2 million in the year-ago period.

Total operating costs in the quarter rose to $7.9 million, compared to $7.7 million one year ago.

As of June 30, Genomica had $115.5 million in cash, investments, and interest receivable on investments.

Last week, the investment firm Harris & Harris Group, responsible for providing seed money for Genomica, sold its nearly 3 percent stake in the company. As GenomeWeb reported, Harris & Harris Group said it planned to use the net proceeds “in other private equity situations.”

Genomica develops and markets software and services designed to enable pharmaceutical and biotechnology researchers to accelerate drug discovery and development.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.